Search

Pacific Biosciences of California Inc

Suletud

SektorTervishoid

1.14 -11.63

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.1400000000000001

Max

1.29

Põhinäitajad

By Trading Economics

Sissetulek

32M

-8.3M

Müük

-7.5M

37M

Aktsiakasum

-0.12

Kasumimarginaal

-22.258

Töötajad

485

EBITDA

33M

-5.8M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+83.08% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

4. nov 2026

Turustatistika

By TradingEconomics

Turukapital

-40M

441M

Eelmine avamishind

12.77

Eelmine sulgemishind

1.14

Uudiste sentiment

By Acuity

50%

50%

156 / 340 Pingereas Healthcare

Pacific Biosciences of California Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. aug 2026, 23:01 UTC

News

Pacific Biosciences reported lower second-quarter revenue and a wider EPS loss, prompting a reduction in full-year sales guidance. Shares are down in after-market trading.

4. aug 2026, 21:36 UTC

Pacific Biosciences of California remained roughly flat after market hours. Broader market gains were driven by a decline in crude oil prices.

3. aug 2026, 23:36 UTC

Pacific Biosciences of California Inc. shares are roughly flat after-market, remaining near the lower end of their one-month trading range.

31. juuli 2026, 19:46 UTC

News
Correlated Moves

Pacific Biosciences of California is trading lower amid a report citing annual sales declines and cash burn concerns impacting its growth outlook.

29. juuli 2026, 16:06 UTC

Correlated Moves

Pacific Biosciences of California Inc shares are lower today, reflecting broader market pressure on small-cap equities and a notable decline in correlated assets.

28. juuli 2026, 16:12 UTC

Pacific Biosciences is trading higher, rebounding from earlier losses despite broader market caution following declines in the Nikkei 225 Index.

27. juuli 2026, 19:06 UTC

Pacific Biosciences is trading higher as the broader market rises, supported by a notable decline in crude oil prices that has eased geopolitical tensions.

24. juuli 2026, 22:31 UTC

Pacific Biosciences shares are higher in after-market trading. No specific company news was identified to explain this movement.

22. juuli 2026, 18:01 UTC

Correlated Moves

Pacific Biosciences of California shares are lower amid broader market pressures and rising crude oil prices, trading below its 20-day moving average.

21. juuli 2026, 13:01 UTC

Pacific Biosciences is rallying in pre-market trading, continuing its upward trend since Monday's close after three sessions of declines. No specific news was identified.

20. juuli 2026, 23:01 UTC

Shares of Pacific Biosciences of California are higher in after-market hours, marking a peak cumulative return since Monday's close amid broader market volatility.

Võrdlus sarnastega

Hinnamuutus

Pacific Biosciences of California Inc Prognoos

Hinnasiht

By TipRanks

83.08% tõus

12 kuu keskmine prognoos

Keskmine 2.38 USD  83.08%

Kõrge 3 USD

Madal 1.5 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Pacific Biosciences of California Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

4 ratings

2

Osta

1

Hoia

1

Müü

Sentiment

By Acuity

156 / 340 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
help-icon Live chat